PCI Pharma Services’ Post

📈 A recent trend we are observing as niche CDMO experts in lyophilisation is that pharmaceutical and biotech companies may initially consider developing liquid drug products to limit investments and move quickly through clinical phase 1. However, they keep in mind a potential switch to a lyophilised version. This approach allows for more effective R&D investments with only minor adjustments. For instance, we would use a lyo-friendly buffer rather than PBS, which is also beneficial for liquid products. We specialise in lyophilisation, but we are also fully equipped to assist companies in liquid formulation development, from products such as HPAPIs to biologics. #CDMO #lyophilisation #freezedrying #pharma #drugproduct

Thoughts on this? >> Merck KGaA stays positive on CDMO arm’s future despite first-quarter slump >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharma #healthcare #pharmaceutical

Dr. Santosh Bhardwaj is presenting how precision and reliability are integrating with new innovations in purity analysis, enhancing the accuracy and effectiveness of the process at the 2nd Annual Pharma Impurity Conclave 2024. #EminenceBusinessMedia #EBMPIC2024 #EminenceGroupVentures

7 Steps To Accelerate Biopharma Manufacturing Processes https://lnkd.in/eMvF3ZPz - By Greg Anthos, Tunnell Consulting, Inc. Delve into strategies for overcoming these challenges, focusing on expedited process characterization and identification of critical material attributes (CMAs), critical process parameters (CPPs), and critical quality attributes (CQAs).

Biotechs Bound for the Carolinas. Cambrex (CDMO) will be opening a new Stability Storage Facility via Q1 Scientific Ltd. in Durham (RTP) which is expected to be operational by the end of 2024 including ultralow temperature storage, with an additional phase coming online in the next couple years. Stability storage involves storing drug substances and products under controlled conditions (temp, humidity, light) to maintain their quality and shelf life. The expansion into Durham is part of Cambrex's strategy to grow its biologics business and meet the increasing demand for stability storage services as well as same day and next day delivery to its clients. #biotech #biotechnology #pharma #lifesciences #coldstorage #stability #cambrex #rtp #ultralow

The landscape of injectable drug development is always evolving, with new trends and challenges emerging constantly – and our leadership team stays at the forefront of all these new developments! Dr. Claus Feussner, SVP of Development Service, recently sat down for a roundtable hosted by DCAT (Drug, Chemical & Associated Technologies Association) to share some of his insights for the Value Chain Insights series. As a member of the DCAT Editorial Committee, this was a valuable opportunity to discuss some of the key trends and issues shaping the #pharma industry, including: • The rise of complex drug formulations 📈 • Evolving regulatory requirements 🌐 • Advances in #asepticfilling technologies ⏏️ Read the full write-up in the article linked below and share your thoughts in the comments! https://lnkd.in/ec-A4MNg

Thoughts on this? >> Siegfried nabs US site from Curia; Merck KGaA pumps €62M more into its HQ >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #healthcare #pharmaceutical #pharma

Companies 𝑐𝑎𝑛 meet their sustainability goals, reduce operating costs, satisfy regulatory requirements, and improve product quality all at once. CRB's Rob Boulanger, PhD, Zach Page-Belknap, and Nick Dove explain how using a systematic approach to close a process, such as the closure risk assessment (CLARA), can lead to reduced cleanroom classifications. This can lower facility space needs by 15% and use less energy and water consumption in cleanrooms. Read their feature in the American Pharmaceutical Review magazine: #LifeSciences #Cleanroom #Pharma #Sustainability

Join me this Sunday at 3:55 pm CT in Room 221 at the Morial Convention Center for my presentation on "Manufacturing Deficiencies in Liquid Drug Products: The Top 10 Issues". I am excited to share my insights on this important topic. Don't miss out! #SCHB #PharmaceuticalManufacturing

Explore how collaboration between biopharma manufacturers and critical material suppliers can guarantee the consistent quality of raw materials, thereby reducing supply chain vulnerabilities and safeguarding patient safety. Learn more about the evidence supporting this effective approach in Jennifer Goodman, MBA's upcoming presentation at DCAT next week.